On June 14, 2022 Patrys reported the publication of new data from a series of studies by our collaborators Dr James Hansen, of Yale School of Medicine and Dr Kim O’Sullivan, of Monash University, showing that PAT‑DX1 suppresses the formation of neutrophil extracellular traps (NETs), which may reduce metastasis in some cancers (Press release, Patrys, JUN 14, 2022, View Source [SID1234615955]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper, which is published in the peer-reviewed journal ImmunoHorizons, is the first study showing that PAT-DX1 may be used to regulate the formation of NETs, which are believed to contribute to immunity, inflammation and the pathophysiology of various inflammatory diseases and some cancers.

Patrys CEO and MD, Dr. James Campbell said:

"This is an unexpected and important discovery for Patrys, offering mechanistic rationale to the previously-described ability of PAT-DX1 to reduce cancer spread by metastasis, and opening the door to broader uses of deoxymabs in non-cancer indications, particularly chronic inflammatory conditions that are driven by NET formation."